Table 1. Characteristics of the study population.
| Type of study population | Characteristics |
No. of
unvaccinated (%) |
Vaccinated with
BBIBP-CorV (%) |
Vaccinated with
CoronaVac (%) |
Vaccinated with BBIBP-CorV
and CoronaVac (%) |
Total (%) | |||||||
| Partially | Completely primary | Partially | Completely primary | Partially | Completely primary | Partially | Completely primary | ||||||
| Close
contacts |
Gender | ||||||||||||
| Male | 232 (49.05) | 51 (66.23) | 97 (45.97) | 59 (49.58) | 135 (40.18) | 5 (55.56) | 122 (51.48) | 115 (56.10) | 354 (45.15) | ||||
| Female | 241 (50.95) | 26 (33.77) | 114 (54.03) | 60 (50.42) | 201 (59.82) | 4 (44.44) | 115 (48.52) | 90 (43.90) | 430 (54.85) | ||||
| Age group (years) | |||||||||||||
| 18–59 | 408 (86.26) | 69 (89.61) | 199 (94.31) | 106 (89.08) | 329 (97.92) | 9 (100) | 212 (89.45) | 184 (89.76) | 740 (94.39) | ||||
| ≥60 | 65 (13.74) | 8 (10.39) | 12 (5.69) | 13 (10.92) | 7 (2.08) | 0 | 25 (10.55) | 21 (10.24) | 44 (5.61) | ||||
| Comorbidities | |||||||||||||
| None | 360 (76.11) | 72 (93.51) | 191 (90.52) | 105 (88.24) | 309 (91.96) | 9 (100) | 213 (89.87) | 186 (90.73) | 713 (90.94) | ||||
| Yes | 113 (23.89) | 5 (6.49) | 20 (9.48) | 14 (11.76) | 27 (8.04) | 0 | 24 (10.13) | 19 (9.27) | 71 (9.06) | ||||
| Total | 473 | 77 | 211 | 119 | 336 | 9 | 237 | 205 | 784 | ||||
| People with infection | Clinical outcome | ||||||||||||
| Asymptomatic | 0 | 0 | 0 | 0 | 1 (5.55) | 0 | 0 | 0 | 1 (2.86) | ||||
| Mild | 13 (21.31) | 1 (25.00) | 3 (33.33) | 3 (42.86) | 10 (55.56) | 0 | 2 (25.00) | 4 (36.36) | 15 (42.86) | ||||
| Moderate | 33 (54.10) | 2 (50.00) | 6 (66.67) | 3 (42.86) | 7 (38.89) | 0 | 4 (50.00) | 5 (45.46) | 17 (48.57) | ||||
| Severe | 9 (14.75) | 1 (25.00) | 0 | 1 (14.28) | 0 | 0 | 2 (25.00) | 2 (18.18) | 2 (5.71) | ||||
| Critical severe | 6 (9.84) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Total | 61 | 4 | 9 | 7 | 18 | 0 | 8 | 11 | 35 | ||||